De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ReShape Lifesciences Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Hickey

Algemeen directeur

US$506.4k

Totale compensatie

Percentage CEO-salaris	73.7%
Dienstverband CEO	2.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

Analyse CEO-vergoeding

Hoe is Paul Hickey's beloning veranderd ten opzichte van ReShape Lifesciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$506k	US$373k	-US$11m
Sep 30 2023	n/a	n/a	-US$26m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$158k	US$133k	-US$46m

Compensatie versus markt: De totale vergoeding ($USD 506.42K ) Paul } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Paul is gestegen terwijl het bedrijf verliesgevend is.

CEO

Paul Hickey (59 yo)

2.2yrs

Tenure

US$506,416

Compensatie

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Dan Gladney	Executive Chair	8.9yrs	US$129.50k	0.0028% $ 69.6
Paul Hickey	CEO, President & Director	2.2yrs	US$506.42k	geen gegevens
Thomas Stankovich	Senior VP & CFO	5yrs	US$307.12k	0.078% $ 2.0k
Mark Knudson	Co-Founder and Special Advisor to the CEO	no data	US$37.50k	geen gegevens
Katherine Tweden	Co-Founder	no data	US$279.30k	geen gegevens
Al Diaz	Vice President of Operations and R&D	3.2yrs	geen gegevens	geen gegevens
Dov Gal	VP of Regulatory Clinical Quality & Compliance Officer	no data	geen gegevens	geen gegevens
Jody Dahlman	Director of Communications	no data	geen gegevens	geen gegevens
Naqeeb Ansari	Senior Vice President of Global Commercial Operations	2.1yrs	US$1.16m	geen gegevens

2.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RSLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dan Gladney	Executive Chair	8.9yrs	US$129.50k	0.0028% $ 69.6
Paul Hickey	CEO, President & Director	2.2yrs	US$506.42k	geen gegevens
Ardaeviraf Minocherhomjee	Independent Director	6.2yrs	US$52.50k	geen gegevens
Gary Blackford	Independent Lead Director	8.2yrs	US$77.00k	geen gegevens
Philip Schauer	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Caroline Apovian	Member of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens
Scott Shikora	Member of Scientific Advisory Board	6.3yrs	US$892.19k	geen gegevens
Lori McDougal	Independent Director	9.3yrs	US$57.50k	geen gegevens
Jaime Ponce	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
John Morton	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Natan Zundel	Member of Scientific Advisory Board	6.3yrs	geen gegevens	geen gegevens
Michael Baptista	Member of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RSLS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

ReShape Lifesciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

Insufficient new directors

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

High number of new directors

Recent updates

Second quarter 2024 earnings released: US$0.063 loss per share (vs US$1.08 loss in 2Q 2023)

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd